Merlin_Asset (@Merlin_Asset) header
Merlin_Asset (@Merlin_Asset) profile picture

“Always Be Learning” - Tweets are not recommendation. Do your own due diligence. Sector and Market Cap Agnostic

Joined April 2015
Capricor $CAPR -68% after hours. FDA rejected deramiocel for Duchenne. It was telegraphed: - July: FDA panel voted 9-3 that the data didn't show efficacy - FDA staff flagged that Capricor changed its analysis after the trial ended I guess lesson is when the analysis plan moves after unblinding, so does your stock.
2
705
Bought $ABVX at $67 on the short-report dip. A once-daily UC pill with 51% remission vs 10% placebo at week 44. NDA due by year-end. And Big Pharma has a patent cliff to fill. Scorpion's betting on a safety scare and likely covered their short given the move. $XBI
3
353
Replying to @TraderPamplona
I was in that camp until you posted the chart of the previous drawdowns. Your target was inline with that. Well done on the call 👍
1
47
On the weekend the FDA rejected $SMMT drug. PFS win, but OS missed: HR 0.79, p=0.057. Not enough. 48 hours later Sellas $SLS hits OS outright in AML: 24.0 vs 14.7 months median survival HR 0.59, p=0.035 The catch: 126 patients, 80 deaths. A small trial, but on the right endpoint. The FDA just told everyone which endpoint it pays for. Sellas plans its BLA for 1H 2027
1
332
The regulator reads the pre-specified analysis, not the follow-up you wish you'd planned. FDA just told $SMMT that PFS isn't enough. China approved the same drug in the same setting in May 2024. Same drug, different bar. $XBI
83
Canadian Natural Resources $CNQ.TO said it agreed to acquire Advantage Energy $AAV.TO for CA$13.55 ($9.49) per share in cash.
132
Quebecor’s $QBR.B.TO offer is worth about C$19.45 per share, valuing Telus $T.TO at around C$31 billion ($21.7 billion). That would be a 60% premium to Friday’s closing share price.
216
Summit $SMMT announced the FDA rejection today for ivonescimab plus chemo in EGFR-mutated lung cancer patients whose earlier targeted drugs stopped working. The FDA wanted a statistically significant survival benefit, and HARMONi didn't show one. $XBI
1
384
CANACCORD $CF.TO ENTERS INTO AGREEMENT TO BE TAKEN PRIVATE BY CHAIRMAN AND CEO DAN DAVIAU Shareholders to receive aggregate consideration of $15.27 per common share comprised of $7.45, plus proceeds of £4.15
3
4
19
4,913
Replying to @ronmortgageguy
When are you going to run for politics Ron? Save us already!
2
230